Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
Boykin, Christi, and Zhang, G., and Chen, Y-H, and Zhang, R-W, and Fan, X-E, and Yang, W-M, and Lu, Q..
"Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation". British Journal of Cancer.
104:5. (781-789.),
March 2011.
May 15, 2021.
http://hdl.handle.net/10342/5298.
Chicago:
Boykin, Christi and Zhang, G. and Chen, Y-H and Zhang, R-W and Fan, X-E and Yang, W-M and Lu, Q.,
"Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation," British Journal of Cancer 104, no.
5 (March 2011),
http://hdl.handle.net/10342/5298 (accessed
May 15, 2021).
AMA:
Boykin, Christi, Zhang, G., Chen, Y-H, Zhang, R-W, Fan, X-E, Yang, W-M, Lu, Q..
Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. British Journal of Cancer.
March 2011;
104(5)
781-789. http://hdl.handle.net/10342/5298. Accessed
May 15, 2021.
